PapersPMID:33437217
Benefits of resistant starch type 2 for patients with end-stage renal disease under maintenance hemodialysis: a systematic review and meta-analysis.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- meta-analysis
No finding here moved its endpoint.
What did not
How to read these marks →“The level of UA did not vary between the RS2 group and the control group (WMD = 0.17, 95% CI: -0.23 to 0.58, I2 = 0%, P = 0.40, Figure 3c).”
- Effect
- 0.17 mean difference, 95% CI −0.23 to 0.58
- Population
- Adult patients with end-stage renal disease on maintenance hemodialysis, pooled from randomized trials; primary outcome
“We found insignificant changes of albumin in the RS2 group (WMD = 0.06, 95% CI: -0.06 to 0.18, I2 = 0%, P = 0.33, Figure 6a).”
- Effect
- 0.06 mean difference, 95% CI −0.06 to 0.18
- Population
- Adult patients with end-stage renal disease on maintenance hemodialysis, pooled from randomized trials; secondary outcome
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adult patients with end-stage renal disease under maintenance hemodialysis; five RCTs of resistant starch type 2 (RS2, from two Ingredion companies, United States and Australia) given for 4 weeks to 2 months against placebo or control
- Participants
- 179
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 9